BACKGROUND: For years, anxiolytics and hypnotics have been one of the most prescribed drug classes in most developed countries. The main aim of this study is to explore the pattern of use of anxiolytic and hypnotic drugs during the period 2000-2011, comparing their growth with that of five european countries. METHOD: We performed an ecological and descriptive study of anxiolytics and hypnotics consumption in Spain. Consumption data were obtained from the databases of medications dispensed in community pharmacies and charged through official prescriptions to the totality of the Spanish National Health System. Annual and total-period consumptions were expressed in defined daily doses (DDD) per 1000 inhabitants per day (DDD/1000 person/day) by each treatment subgroup, active substance and attending the plasma half-life of the medication. Approximate comparisons were also made with some European countries. RESULTS: The use of anxiolytics and hypnotics drugs was 56.7 DDD/1000 person/day in 2000 and 82.9 DDD/1000 person/day in 2011 (a +46.1% increase across the period). Lorazepam and alprazolam were the most used anxiolytics (20.5 and 15.6 DDD/1000 person/day in 2011, respectively), whereas lormetazepam was among the hypnotics (18.3 DDD/1000 person/day in 2011). In relative terms, hypnotics´ lormetazepam and zolpidem increased their use by 103.3% and 85.1%, respectively; while anxiolytics´ lorazepam and hydroxyzine increased 75.1% and 72.8%, respectively. In Spain (period 2003-2010), the total increase in the consumption of anxiolytics and hypnotics was +34.3%, with 24.0% for Portugal, 4.0% for Italy, but a reduction of -6.1% for France. CONCLUSIONS: A considerable increase in anxiolytics and hypnotics´ consumption has occurred in Spain during the last decade, being the growth higher than that reported in other European countries.
BACKGROUND: For years, anxiolytics and hypnotics have been one of the most prescribed drug classes in most developed countries. The main aim of this study is to explore the pattern of use of anxiolytic and hypnotic drugs during the period 2000-2011, comparing their growth with that of five european countries. METHOD: We performed an ecological and descriptive study of anxiolytics and hypnotics consumption in Spain. Consumption data were obtained from the databases of medications dispensed in community pharmacies and charged through official prescriptions to the totality of the Spanish National Health System. Annual and total-period consumptions were expressed in defined daily doses (DDD) per 1000 inhabitants per day (DDD/1000 person/day) by each treatment subgroup, active substance and attending the plasma half-life of the medication. Approximate comparisons were also made with some European countries. RESULTS: The use of anxiolytics and hypnotics drugs was 56.7 DDD/1000 person/day in 2000 and 82.9 DDD/1000 person/day in 2011 (a +46.1% increase across the period). Lorazepam and alprazolam were the most used anxiolytics (20.5 and 15.6 DDD/1000 person/day in 2011, respectively), whereas lormetazepam was among the hypnotics (18.3 DDD/1000 person/day in 2011). In relative terms, hypnotics´ lormetazepam and zolpidem increased their use by 103.3% and 85.1%, respectively; while anxiolytics´ lorazepam and hydroxyzine increased 75.1% and 72.8%, respectively. In Spain (period 2003-2010), the total increase in the consumption of anxiolytics and hypnotics was +34.3%, with 24.0% for Portugal, 4.0% for Italy, but a reduction of -6.1% for France. CONCLUSIONS: A considerable increase in anxiolytics and hypnotics´ consumption has occurred in Spain during the last decade, being the growth higher than that reported in other European countries.
Authors: Pilar Carrasco-Garrido; Valentín Hernández-Barrera; Isabel Jiménez-Trujillo; Jesús Esteban-Hernández; Alejandro Álvaro-Meca; Ana López-de Andrés; José Luis DelBarrio-Fernández; Rodrigo Jiménez-García Journal: Int J Environ Res Public Health Date: 2016-11-24 Impact factor: 3.390
Authors: Clara Maestre-Miquel; Ana López-de-Andrés; Zichen Ji; Javier de Miguel-Diez; Arturo Brocate; Sara Sanz-Rojo; Antonio López-Farre; David Carabantes-Alarcon; Rodrigo Jiménez-García; José J Zamorano-León Journal: Int J Environ Res Public Health Date: 2021-06-11 Impact factor: 3.390
Authors: Miguel Angel Fernández García; Antonio Olry de Labry Lima; Ingrid Ferrer Lopez; Clara Bermúdez-Tamayo Journal: J Pharm Policy Pract Date: 2018-01-16
Authors: Caterina Vicens; Alfonso Leiva; Ferran Bejarano; Ermengol Sempere; Raquel María Rodríguez-Rincón; Francisca Fiol; Marta Mengual; Asunción Ajenjo; Fernando Do Pazo; Catalina Mateu; Silvia Folch; Santiago Alegret; Jose Maria Coll; María Martín-Rabadán; Isabel Socias Journal: BMJ Open Date: 2019-01-30 Impact factor: 2.692